Last updated: February 14, 2026
Overview
NDC 00115-1694 is the drug Humira (Adalimumab), a monoclonal antibody primarily used for autoimmune conditions such as rheumatoid arthritis, Crohn's disease, and psoriatic arthritis. Humira is among the top-selling drugs globally, with significant market penetration. Patent expirations and biosimilar entries are influencing the pricing landscape and projected market growth.
Market Size and Segments
Humira's revenue peaked at $20.3 billion in 2021, accounting for a substantial share of the biologics market. The drug's primary segments include:
- Rheumatoid arthritis (RA): 40%
- Crohn's disease: 25%
- Psoriasis: 15%
- Other immune-mediated conditions: 20%
Current Market Dynamics
- Patent Expiry: The U.S. patent expired in January 2023 for Humira’s original formulation, opening the market to biosimilars.
- Biosimilar Entry: Several biosimilars launched in the U.S. and Europe in 2023, with pricing about 15-30% lower than the reference product.
- Market Penetration: Over 10 biosimilars approved by the FDA as of Q2 2023, with increasing uptake in biosimilar-preferred formularies.
- Manufacturing: Multiple manufacturers now produce biosimilars, increasing competition and driving prices downward.
Price Trends and Projections
Current Pricing (U.S.):
- Humira (Brand): Average wholesale price (AWP) is approximately $6,000 per 40 mg pen or pre-filled syringe.
- Biosimilar versions: Average launch prices range from $4,200 to $5,100, representing an immediate 15-30% discount.
Historical Price Trajectory:
| Year |
Humira Price (per 40 mg dose) |
Notes |
| 2018 |
~$5,800 |
Peak pricing in the U.S. |
| 2022 |
~$6,150 |
Slight increase driven by inflation and manufacturing costs. |
| 2023 |
$4,200 – $5,100 (biosimilars) |
Entry of biosimilars significantly lowers price. |
Projected Trends (2024-2028):
- Price stabilization: As biosimilar market share increases, brand price may decline slightly, stabilizing around $3,500-$4,500.
- Market share Shift: Biosimilars expected to command over 60% of prescriptions by 2025, further pressuring brand pricing.
- Price erosion rate: Approximately 10-15% annually over the next five years, consistent with biosimilar market patterns.
Revenue Projections
| Year |
Estimated U.S. Sales |
Biosimilar Market Share |
Projected Revenue (Humira vs. Biosimilars) |
| 2023 |
~$8 billion |
40% |
Humira: ~$3.2 billion; Biosimilars: ~$4.8 billion |
| 2024 |
~$7.2 billion |
50% |
Humira: ~$3.6 billion; Biosimilars: ~$3.6 billion |
| 2025 |
~$6.5 billion |
60% |
Humira: ~$2.6 billion; Biosimilars: ~$3.9 billion |
| 2026 |
~$5.8 billion |
70% |
Humira: ~$1.7 billion; Biosimilars: ~$4.1 billion |
| 2027 |
~$5.2 billion |
75% |
Humira: ~$1.3 billion; Biosimilars: ~$3.9 billion |
Note: These figures assume steady uptake, no new patent disputes or regulatory delays.
Competitive Landscape
- Pfizer's Cimzia and Amgen's Amjevita are primary biosimilar competitors.
- Price competition is intensifying with other biosimilar entrants from Samsung Bioepis, Coherus Biosciences, and Sandoz.
- Payor strategies favor biosimilars, with formulary shifts further reducing Humira's market share.
Regulatory and Policy Impact
- The Inflation Reduction Act and subsequent policies in the U.S. encourage biosimilar adoption.
- FDA's accelerated approval pathways facilitate quicker biosimilar approval.
- Patent litigations and settlements may affect market dynamics.
Risks and Opportunities
- Risks: Patent litigations, supply chain disruptions, slower-than-expected biosimilar adoption.
- Opportunities: Expanded indications, combination therapy approvals, strategic partnerships to accelerate biosimilar uptake.
Key Takeaways
- Humira's market is transitioning due to biosimilar competition, with prices declining markedly since 2023.
- Prices are projected to decline further through 2028, impacting revenues.
- The biosimilar market is expanding, reaching over 60% of prescriptions expected by 2025.
- Competition and regulatory trends favor biosimilar maturation, reducing Humira’s dominance.
- Cost savings for payors and consumers will continue to influence purchasing behaviors.
FAQs
1. How will biosimilar entry impact Humira's market share?
Biosimilar entry has reduced Humira's market share from over 90% pre-2023 to an estimated 40% in 2023, with further erosion expected as biosimilar penetration increases.
2. What is the expected price range for biosimilars over the next five years?
Biosimilars are projected to be priced between $3,500 and $4,200 per 40 mg dose, representing a 15-30% discount compared to brand prices.
3. Will the total revenue for Humira decline significantly?
Yes, as biosimilar market share grows, total revenue for Humira is expected to decrease from over $8 billion in 2023 to approximately $5 billion or less by 2027.
4. What factors could alter these projections?
Regulatory delays, patent litigations, supply chain issues, or slower biosimilar adoption could slow price declines and revenue erosion.
5. Are new indications influencing the market outlook?
Yes, approval of Humira for additional indications like hidradenitis suppurativa and ulcerative colitis could stabilize demand, but biosimilar pressure remains dominant.
Sources
[1] IQVIA Market Data, 2023.
[2] FDA Biologics Approvals, 2023.
[3] Evaluate Pharma, "Biologic Market Outlook," 2023.
[4] Centers for Medicare & Medicaid Services (CMS), Formularies and Reimbursement Policies, 2023.
[5] S&P Capital IQ, Biotech Pricing Trends, 2023.
